Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for multiple sclerosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Progressive multiplesclerosis: prospects for disease therapy, repair, and restoration of function. Multiplesclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting multiplesclerosis, the gradual accumulation of disability that characterises progressive multiplesclerosis seems to result more from diffuse (...) immune mechanisms and neurodegeneration. As a result, the 14 anti-inflammatory drugs that have regulatory approval for treatment of relapsing-remitting multiplesclerosis have little or no efficacy in progressive multiplesclerosis without inflammatory lesion activity. Effective therapies for progressive multiplesclerosis that prevent worsening, reverse damage, and restore function are a major unmet need. In this Series paper we summarise the current status of therapy for progressive multiple
Evolving concepts in the treatment of relapsing multiplesclerosis. In the past 20 years the treatment scenario of multiplesclerosis has radically changed. The increasing availability of effective disease-modifying therapies has shifted the aim of therapeutic interventions from a reduction in relapses and disability accrual, to the absence of any sign of clinical or MRI activity. The choice for therapy is increasingly complex and should be driven by an appropriate knowledge of the mechanisms
Disease modifying therapies for relapsing multiplesclerosis. Multiplesclerosis (MS) is a common, disabling, putatively autoimmune neurological disease with worldwide distribution. It typically begins as a relapsing disorder that later evolves to a secondary progressive phase. Inflammatory and neurodegenerative mechanisms seem to operate in both phases, but their relative contributions and interactions are incompletely understood. Disease modifying therapies (DMTs) approved for relapsing (...) multiplesclerosis interfere with a variety of immunological mechanisms to reduce rates of relapse, accumulation of disease burden measured by magnetic resonance imaging (MRI), and decline in neurological function over the two to three year duration of typical randomized controlled trials. Benefits of longer duration of therapy on disability are less clear, as data beyond three years are largely limited to observational studies. However, current DMTs do not slow accrual of disability once progressive
Daclizumab (Zinbryta) - multiplesclerosis Zinbryta (daclizumab) Injection U.S. Department of Health and Human Services Search FDA Submit search Zinbryta (daclizumab) Injection Zinbryta Company: Biogen Inc. Application No.: 761029 Approval Date: 05/27/2016 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: July 7, 2016 Vision
Association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with multiplesclerosis risk: A meta-analysis. Multiplesclerosis (MS) is a major demyelinating disease of the central nervous system with a strong genetic component. Previous studies have reported that the association of EVI5 rs11808092, CD58 rs2300747, and CIITA rs3087456 polymorphisms with the susceptibility to MS. However, the results were inconsistent. Thus, we conducted this meta-analysis to provide a more (...) , P < 0.01; heterozygous: OR = 0.85, 95% CI = 0.76-0.94, P < 0.01, and dominant: OR = 0.84, 95% CI = 0.76-0.93, P < 0.01). However, this meta-analysis indicated that CIITA rs3087456 polymorphism was not related to multiple sclerosis.The mutant alleles of EVI5 rs11808092 polymorphism may increase the susceptibility to MS while those of CD58 rs2300747 polymorphism may decrease MS risk. In addition, CIITA rs3087456 polymorphism might not be associated with MS.
The Effectiveness of Group Cognitive Behavioral Therapy in Treating Obsessive-Compulsive Disorder in Women with MultipleSclerosis (MS): A randomized double-blind controlled trial. Obsessive-compulsive disorder (OCD) is one of the most prevalent psychiatric disorders and can cause problems for individuals in all aspects of life, including social and personal dimensions.To study the effect of group cognitive-behavioral therapy on the reduction of OCD symptoms in female participants with multiple (...) sclerosis (MS).This double-blind randomized control trial was conducted from May 2012 to December 2014. The participants included 75 patients with MS who suffered from OCD and were referred to the Loghman Hakim and Imam Khomeini hospitals in Tehran, Iran. Thirty participants had been diagnosed through Yale-Brown Obsessive-Compulsive Symptoms (Y-BOCS). The participants were randomly divided into an experimental group (n=15) and a control group (n=15). Eleven sessions of cognitive-behavioral therapy were
Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in MultipleSclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in MultipleSclerosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in MultipleSclerosis: Clinical Effectiveness and Guidelines Delta-9-tetrahydrocannabinol/Cannabidiol for Spasticity in MultipleSclerosis: Clinical Effectiveness (...) and Guidelines Published on: May 4, 2016 Project Number: RB0983-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question 1. What is the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with MultipleSclerosis? 2. What are the evidence-based guidelines associated with delta-9-tetrahydrocannabinol/cannabidiol for the treatment of spasticity in patients with MultipleSclerosis? Key Message Three systematic
Modifiable Risk Factors in the Progression of MultipleSclerosis Management Briefs eBrief-no111 -- Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no111 -- Health Services Research & Development Management eBrief no. 111 » Issue 111 April 2016 The report is a product of the VA/HSR&D Evidence Synthesis Program. Systematic Review: Modifiable Risk Factors in the Progression (...) of MultipleSclerosisMultiplesclerosis (MS) is the most common progressive disease of the central nervous system in young adults and the cause of serious physical disability in adults of working age. MS disease presentation is very heterogeneous with variable clinical manifestations that evolve over time. In about 50 percent of patients the course of MS changes from relapsing-remitting to secondary progressive disease after ten years. Relapsing-remitting disease manifests in relapses followed by periods
Fingolimod for relapsing-remitting multiplesclerosis. Fingolimod was approved in 2010 for the treatment of patients with the relapsing-remitting (RR) form of multiplesclerosis (MS). It was designed to reduce the frequency of exacerbations and to delay disability worsening. Issues on its safety and efficacy, mainly as compared to other disease modifying drugs (DMDs), have been raised.To assess the safety and benefit of fingolimod versus placebo, or other disease-modifying drugs (DMDs (...) ), in reducing disease activity in people with relapsing-remitting multiplesclerosis (RRMS).We searched the Cochrane MultipleSclerosis and Rare Diseases of the Central Nervous System (CNS) Group's Specialised Trials Register and US Food and Drug Administration reports (15 February 2016).Randomised controlled trials (RCTs) assessing the beneficial and harmful effects of fingolimod versus placebo or other approved DMDs in people with RRMS.We used standard methodological procedures as expected by Cochrane.Six
Alemtuzumab for multiplesclerosis. Multiplesclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating exacerbations, preventing new exacerbations and avoiding the progression of disability. However, at present there is no effective treatment that is capable of safely and effectively reaching these objectives. This has led to the development and investigation of new (...) drugs. Recent clinical trials suggest that alemtuzumab, a humanised monoclonal antibody against cell surface CD52, could be a promising option for MS.To assess the safety and effectiveness of alemtuzumab used alone or associated with other treatments to decrease disease activity in patients with any form of MS.We searched the Trials Register of the Cochrane MultipleSclerosis and Rare Diseases of the CNS Group (30 April 2015), which contains trials from the Cochrane Central Register of Controlled
Evaluation of KIR4.1 as an Immune Target in MultipleSclerosis. 27074083 2016 04 25 2018 11 13 1533-4406 374 15 2016 Apr 14 The New England journal of medicine N. Engl. J. Med. Evaluation of KIR4.1 as an Immune Target in MultipleSclerosis. 1495-6 10.1056/NEJMc1513302 Chastre Anne A Yale School of Medicine, New Haven, CT firstname.lastname@example.org. Hafler David A DA Yale School of Medicine, New Haven, CT email@example.com. O'Connor Kevin C KC Yale School of Medicine, New Haven, CT (...) NIH HHS United States U19 AI046130 AI NIAID NIH HHS United States GM093080 GM NIGMS NIH HHS United States Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 0 Antibodies, Monoclonal 0 Autoantibodies 0 Biomarkers 0 Kcnj10 (channel) 0 Potassium Channels, Inwardly Rectifying AIM IM Antibodies, Monoclonal Autoantibodies blood Biomarkers blood Case-Control Studies Enzyme-Linked Immunosorbent Assay Humans MultipleSclerosis diagnosis
Memory rehabilitation for people with multiplesclerosis. This is an update of the Cochrane review 'Memory rehabilitation for people with multiplesclerosis' (first published in the Cochrane Library 14 March 2012, Issue 3). Impairments in cognitive function, particularly memory, are common in people with multiplesclerosis (MS) and can potentially affect their ability to complete functional activities. There is evidence from single-case or small group studies that memory rehabilitation can (...) Specialised Register of the Cochrane MultipleSclerosis and Rare Diseases of the CNS Group (2 June 2015) and the following electronic databases: The NIHR Clinical Research Network Portfolio database (NIHR CRN) (from 2010 to June 2015), The Allied and Complementary Medicine Database (AMED) (2010 to June 2015), British Nursing Index (BNI) (2010 to June 2015), PsycINFO (2011 to June 2015), and CAB Abstracts (2010 to June 2015). Start dates for the electronic databases coincided with the last search
Teriflunomide for multiplesclerosis. This is an update of the Cochrane review "Teriflunomide for multiplesclerosis" (first published in The Cochrane Library 2012, Issue 12).Multiplesclerosis (MS) is a chronic immune-mediated disease of the central nervous system. It is clinically characterized by recurrent relapses or progression, or both, often leading to severe neurological disability and a serious decline in quality of life. Disease-modifying therapies (DMTs) for MS aim to prevent (...) , fingolimod, dimethyl fumarate, alemtuzumab) for modifying the disease course in people with MS.We searched the Cochrane MultipleSclerosis and Rare Diseases of the CNS Group Specialised Trials Register (30 September 2015). We checked reference lists of published reviews and retrieved articles and searched reports (2004 to September 2015) from the MS societies in Europe and America. We also communicated with investigators participating in trials of teriflunomide and the pharmaceutical company, Sanofi
Vitamin D for the Treatment or Prevention of MultipleSclerosis: A Review of the Clinical Effectiveness Vitamin D for the Treatment or Prevention of MultipleSclerosis: A Review of the Clinical Effectiveness | CADTH.ca Find the information you need Vitamin D for the Treatment or Prevention of MultipleSclerosis: A Review of the Clinical Effectiveness Vitamin D for the Treatment or Prevention of MultipleSclerosis: A Review of the Clinical Effectiveness Published on: March 10, 2016 Project (...) Number: RC0755-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of vitamin D supplementation for the prevention of multiplesclerosis? What is the clinical effectiveness of high versus low dose vitamin D supplementation for the prevention of multiplesclerosis? What is the clinical effectiveness of vitamin D supplementation for the treatment of multiplesclerosis? What is the clinical effectiveness
Association of Immunotherapies With Outcomes in Relapsing-Remitting MultipleSclerosis. What immunotherapies for multiplesclerosis are associated with the greatest benefit and highest risk of discontinuation due to adverse events in patients with relapsing-remitting multiplesclerosis?Alemtuzumab, natalizumab, and fingolimod were associated with the greatest benefit with regard to relapse prevention. Their association with prevention of disability worsening was unclear. Fingolimod
Multiplesclerosis following a spinal cord injury: a rare and unfortunate case This is a case report and review of literature with the objective report of the case of a young man with physical disability following a traumatic spinal cord injury (SCI) who was later newly diagnosed with multiplesclerosis (MS) in an inpatient SCI rehabilitation center. (Barcelona, Spain). A 24-year-old male sustained a traumatic spinal cord lesion (T9 AIS A) as the result of a motorcycle accident. He completed (...) MRI revealed multiple demyelinating lesions suggestive of MS. The diagnosis of MS was confirmed by a neurologist and treatment was started with daily doses of glatiramer acetate. At this time the patient was still independent in transfers, activities of daily living and wheelchair management. In young patients with SCI, adequate follow-up is important to detect subsequent complications that may lead to clinical and functional deterioration with a view to uncommon causes such as MS.
Daclizumab (Zinbryta) for the treatment of relapsing (recidive) forms of multiplesclerosis (RMS) Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiplesclerosis (RMS) | Report | National Health Care Institute You are here: Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms of multiplesclerosis (RMS) Search within English part of National Health Care Institute Search Daclizumab (Zinbryta®) for the treatment of relapsing (recidive) forms (...) of multiplesclerosis (RMS) Zorginstituut Nederland carried out a marginal assessment of the medicine daclizumab (Zinbryta ® ), whereby they came to the following conclusion. Based on the criteria of the Medicines Reimbursement System (GVS), daclizumab is interchangeable with interferon beta products (interferon beta-1a, interferon beta-1b, peginterferon beta-1a) and glatiramer acetate (Copaxone ® ), which are included in the GVS. Share this page Service About this site
The Use of Kinect to Improve Balance and Postural Control in Patients with MultipleSclerosis "The Use of Kinect to Improve Balance and Postural Control in Patients " by Theresa R. Jones < > > > > > Title Author Date of Graduation Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Saje Davis-Risen Second Advisor Annjanette Sommers Rights . Abstract Background: Multiplesclerosis (MS) is a leading cause of disability in young (...) improves balance and postural control in MS patients. Methods: An exhaustive literature search using MEDLINE-Ovid, Web of Science and CINAHL was performed using keywords: multiplesclerosis, Xbox, and Kinect. All articles were screened with eligibility criteria. The remaining relevant articles were assessed for quality using GRADE. Results: Two studies met eligibility criteria and were included in this systematic review. Each study was a randomized controlled trial. Both studies demonstrated
The Use of Amphetamines for Improving Cognitive Impairment in Patients with MultipleSclerosis "The Use of Amphetamines for Improving Cognitive Impairment in Patients" by Hayley Kum < > > > > > Title Author Date of Graduation Summer 8-13-2016 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Elizabeth Crawford, PA-C, MS Second Advisor Annjanette Sommers, PA-C, MS Rights . Abstract Background: Multiplesclerosis (MS) is an autoimmune disorder (...) that results in debilitating cognitive impairment in 40-65% of patients. There are no current treatments for this symptom of MS. This is a systematic review of literature on the impact amphetamines have on cognitive function of MS patients. Methods: An exhaustive search of available medical literature was conducted using MEDLINE-Ovid, MEDLINE-PubMed, Web of Science, and CINAHL. Keywords used included: amphetamines and multiplesclerosis. Relevant articles were assessed for quality using GRADE. Results